Literature DB >> 10548505

Activated T lymphocytes support osteoclast formation in vitro.

N J Horwood1, V Kartsogiannis, J M Quinn, E Romas, T J Martin, M T Gillespie.   

Abstract

Osteoblastic stromal cells are capable of supporting osteoclast formation from hematopoietic precursors in the presence of osteotropic factors such as 1alpha,25(OH)(2)D(3), PTH, and IL-11. Osteoblastic stromal cells produce receptor activator of NF-kappaB ligand (RANKL), a type II membrane protein of the TNF ligand family, in response to these agents. Activated T lymphocytes also produce RANKL; however, the ability of this cell type to support osteoclast formation in vitro is unknown. Human PBMC-derived T cells, extracted using alphaCD3-coated magnetic beads, were cocultured with adherent murine spleen cells in the presence of Con A and a panel of cytokines. In the presence of Con A, bona fide osteoclasts were formed in vitro with activated T cells: IL-1alpha and TGFbeta further enhanced osteoclast numbers. PBMC-derived lymphocytes showed an increase in the mRNA expression of RANKL within 24 h of treatment with the same agents that were used to induce osteoclast formation. In synovial tissue sections with lymphoid infiltrates from RA patients, the expression of RANKL was demonstrated in CD3(+) T cells. The ability of activated T lymphocytes to support osteoclast formation may provide a mechanism for the potentiation of osteoclast formation and bone resorption in disease states such as rheumatoid arthritis. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10548505     DOI: 10.1006/bbrc.1999.1623

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  112 in total

Review 1.  The final pathogenetic steps in focal bone erosions in rheumatoid arthritis.

Authors:  S R Goldring
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha.

Authors:  S Cenci; M N Weitzmann; C Roggia; N Namba; D Novack; J Woodring; R Pacifici
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 3.  Hypercalcemia of malignancy.

Authors:  V Grill; T J Martin
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 4.  Osteoprotegerin.

Authors:  U Feige
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

5.  Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis.

Authors:  Nathalie Saidenberg-Kermanac'h; Natacha Bessis; Delphine Lemeiter; Marie-Christine de Vernejoul; Marie-Christophe Boissier; Martine Cohen-Solal
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

6.  Interactions between the immune system and bone.

Authors:  Patrizia D'Amelio; Giorgia Fornelli; Ilaria Roato; Giovanni Carlo Isaia
Journal:  World J Orthop       Date:  2011-03-18

Review 7.  Osteoclastogenesis and arthritis.

Authors:  Nicola Maruotti; Maria Grano; Silvia Colucci; Francesca d'Onofrio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2010-11-11       Impact factor: 3.984

8.  1,25-Dihydroxyvitamin D3 modulates T cell differentiation and impacts on the production of cytokines from Chinese Han patients with early rheumatoid arthritis.

Authors:  Hong-Yan Wen; Jing Luo; Xiao-Feng Li; Dan-Dan Wei; Yang Liu
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

9.  Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency.

Authors:  Jinhu Xiong; Marilina Piemontese; Jeff D Thostenson; Robert S Weinstein; Stavros C Manolagas; Charles A O'Brien
Journal:  Bone       Date:  2014-06-14       Impact factor: 4.398

Review 10.  Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit.

Authors:  Natalie A Sims; T John Martin
Journal:  Bonekey Rep       Date:  2014-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.